Found: 39
Select item for more details and to access through your institution.
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF‐AD study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. 10, p. 6722, doi. 10.1002/alz.14098
- By:
- Publication type:
- Article
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF‐AD Multimodal Biomarker Discovery study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.080072
- By:
- Publication type:
- Article
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non‐Alzheimer's disease pathophysiology.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 3, p. 807, doi. 10.1002/alz.12713
- By:
- Publication type:
- Article
CSF proteomic profiling of mild cognitive impairment individuals with suspected non‐Alzheimer's disease pathophysiology: Developing topics.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.047247
- By:
- Publication type:
- Article
Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid: Molecular and cell biology/synaptic disruption.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.046102
- By:
- Publication type:
- Article
Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, n. 7, p. 888, doi. 10.1016/j.jalz.2019.04.001
- By:
- Publication type:
- Article
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, n. 6, p. 742, doi. 10.1016/j.jalz.2019.01.015
- By:
- Publication type:
- Article
Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, n. 5, p. 644, doi. 10.1016/j.jalz.2019.01.004
- By:
- Publication type:
- Article
P2‐270: INCREASED CSF AMYLOID‐β 1‐38 AND 1‐40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P780, doi. 10.1016/j.jalz.2018.06.959
- By:
- Publication type:
- Article
F1‐02‐01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT‐LIGHT AND YKL‐40 TO Aβ, APOE ε4 AND COGNITION: RESULTS FROM THE EMIF‐AD MULTIMODAL BIOMARKER DISCOVERY STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P201, doi. 10.1016/j.jalz.2018.06.2307
- By:
- Publication type:
- Article
Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
- Published in:
- Alzheimer's Research & Therapy, 2020, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13195-020-00718-y
- By:
- Publication type:
- Article
Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
- Published in:
- Alzheimer's Research & Therapy, 2017, v. 9, p. 1, doi. 10.1186/s13195-017-0328-9
- By:
- Publication type:
- Article
Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, n. 8, p. 903, doi. 10.1016/j.jalz.2016.12.015
- By:
- Publication type:
- Article
EFFECTS OF RISPERIDONE AND GALANTAMINE TREATMENT ON ALZHEIMER BIOMARKER LEVELS IN CEREBROSPINAL FLUID.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1047, doi. 10.1016/j.jalz.2017.06.1487
- By:
- Publication type:
- Article
PREVALENCE OF VASCULAR RISK FACTORS IN DIFFERENT STAGES OF PRODROMAL ALZHEIMER’S DISEASE AND ITS INFLUENCE ON COGNITIVE DECLINE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1059, doi. 10.1016/j.jalz.2016.06.2213
- By:
- Publication type:
- Article
Why Alzheimer patients and caregivers participate in randomized clinical trials
- Published in:
- 2009
- By:
- Publication type:
- Abstract
P2-130: Correlation of inflammatory factors with Alzheimer biomarkers
- Published in:
- 2006
- By:
- Publication type:
- Abstract
O3-05-08: A randomized double-blind trial with omega-3 fatty acid treatment in mild to moderate Alzheimer’s disease
- Published in:
- 2006
- By:
- Publication type:
- Abstract
P2-130: Correlation of inflammatory factors with Alzheimer biomarkers
- Published in:
- 2006
- By:
- Publication type:
- Abstract
O3-05-08: A randomized double-blind trial with omega-3 fatty acid treatment in mild to moderate Alzheimer’s disease
- Published in:
- 2006
- By:
- Publication type:
- Abstract
Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood Mononuclear Leukocytes: The OmegAD Study.
- Published in:
- PLoS ONE, 2012, v. 7, n. 4, p. 1, doi. 10.1371/journal.pone.0035425
- By:
- Publication type:
- Article
Galantamine versus Risperidone for Agitation in People with Dementia: A Randomized, Twelve-Week, Single-Center Study.
- Published in:
- Dementia & Geriatric Cognitive Disorders, 2014, v. 38, n. 3/4, p. 234, doi. 10.1159/000362204
- By:
- Publication type:
- Article
Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer’s Disease: The OmegAD Study.
- Published in:
- Dementia & Geriatric Cognitive Disorders, 2009, v. 27, n. 5, p. 481, doi. 10.1159/000218081
- By:
- Publication type:
- Article
Higher CSF/serum free‐T4 ratio is associated with improvement of quality of life during treatment with L‐thyroxine.
- Published in:
- Journal of Neuroendocrinology, 2023, v. 35, n. 5, p. 1, doi. 10.1111/jne.13272
- By:
- Publication type:
- Article
Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data.
- Published in:
- Frontiers in Aging Neuroscience, 2018, p. N.PAG, doi. 10.3389/fnagi.2018.00193
- By:
- Publication type:
- Article
Low background and high contrast PET imaging of amyloid-β with [C]AZD2995 and [C]AZD2184 in Alzheimer's disease patients.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2013, v. 40, n. 4, p. 580, doi. 10.1007/s00259-012-2322-6
- By:
- Publication type:
- Article
Detection of amyloid in Alzheimer’s disease with positron emission tomography using [<sup>11</sup>C]AZD2184.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2009, v. 36, n. 11, p. 1859, doi. 10.1007/s00259-009-1182-1
- By:
- Publication type:
- Article
CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals.
- Published in:
- Proteomes, 2021, v. 9, n. 3, p. 36, doi. 10.3390/proteomes9030036
- By:
- Publication type:
- Article
Agitation and impulsivity in mid and late life as possible risk markers for incident dementia.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2020, v. 6, n. 1, p. 1, doi. 10.1002/trc2.12016
- By:
- Publication type:
- Article
Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition.
- Published in:
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022, v. 14, n. 1, p. 1, doi. 10.1002/dad2.12286
- By:
- Publication type:
- Article
Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels.
- Published in:
- Dementia & Geriatric Cognitive Disorders Extra, 2014, v. 4, n. 2, p. 335, doi. 10.1159/000363500
- By:
- Publication type:
- Article
Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
- Published in:
- Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00799-3
- By:
- Publication type:
- Article
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
- Published in:
- International Journal of Geriatric Psychiatry, 2008, v. 23, n. 2, p. 161, doi. 10.1002/gps.1857
- By:
- Publication type:
- Article
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
- Published in:
- Molecular Neurodegeneration, 2022, v. 17, n. 1, p. 1, doi. 10.1186/s13024-022-00521-3
- By:
- Publication type:
- Article
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
- Published in:
- Molecular Neurodegeneration, 2022, v. 17, n. 1, p. 1, doi. 10.1186/s13024-022-00521-3
- By:
- Publication type:
- Article
Omega-3 Fatty Acid Supplementation Effects on Weight and Appetite in Patients with Alzheimer's Disease: The Omega-3 Alzheimer's Disease Study.
- Published in:
- Journal of the American Geriatrics Society, 2009, v. 57, n. 1, p. 11, doi. 10.1111/j.1532-5415.2008.02055.x
- By:
- Publication type:
- Article